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Abstract
Background: The b2-adrenergic receptor (ADRB2) gene has been widely researched as a candidate gene for essential
hypertension (EH), but no consensus has been reached in different ethnicities. The aim of the present study was to evaluate
the possible association between the ADRB2 gene polymorphisms and the EH risk in the Northern Han Chinese population.
Methodology/Principal Findings: This study included 747 hypertensive subjects and 390 healthy volunteers as control
subjects in the Northern Han Chinese. Genotyping was performed to identify the C-47T, A46G and C79G polymorphisms of
the ADRB2 gene. G allelic frequency of A46G polymorphism was significantly higher in hypertensive subjects (P=0.011,
OR=1.287, 95%CI [1.059–1.565]) than that in controls. Significant association could also be found in dominant genetic
model (GG+AG vs. AA, P=0.006, OR=1.497, 95%CI [1.121–1.998]), in homozygote comparison (GG vs. AA, P=0.025,
OR=1.568, 95%CI [1.059–2.322]), and in additive genetic model (GG vs. AG vs. AA, P=0.012, OR=1.282, 95%CI [1.056–
1.555]). Subgroup analyses performed by gender suggested that this association could be found in male, but not in female.
Stratification analyses by obesity showed that A46G polymorphism was related to the prevalence of hypertension in the
obese population (GG vs. AG vs. AA, P,0.001, OR=1.645, 95%CI [1.258–2.151]). Significant interaction was found between
A46G genotypes and body mass index on EH risk. No significant association could be found between C-47T or C79G
polymorphism and EH risk. Linkage disequilibrium was detected between the C-47T, A46G and C79G polymorphisms.
Haplotype analyses observed that the T-47-A46-C79 haplotype was a protective haplotype for EH, while the T-47-G46-C79
haplotype increased the risk.
Conclusions/Significances: We revealed that the ADRB2 A46G polymorphism might increase the risk for EH in the Northern
Han Chinese population.
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Introduction
Essential hypertension (EH) is a worldwide escalating problem.
In China, it was reported that 27.2% of the adult population age
35 to 74 years suffered from it [1]. EH is a highly heterogeneous
disorder, which points to a multi-factorial aetiology and polygenic
abnormalities [2]. As a consequence, a lot of gene polymorphisms
have been assessed as candidate determinants of the risk of
hypertension. In the search for the inheritable determinants of EH
phenotype in humans, the gene encoding for the b2-adrenergic
receptor (ADRB2) has been investigated worldwide, since in
hypertension vascular responses to ADRB2 stimulation are
impaired [3,4] and the ADRB2 gene polymorphisms appear to
affect vasodilation [5,6].
At the molecular level, the role of the ADRB2 gene in
hypertension has been extensively evaluated. In vitro, the research
[7] on the single-nucleotide polymorphisms (SNPs) in the
coding region suggested that Arg16RGly (rs1042713, A46G),
Gln27RGlu (rs1042714, C79G), and Arg16RGly +Gln27RGlu,
compared to wild-type ADRB2, displayed normal agonist binding
and functional coupling to the stimulatory form of G protein (Gs),
resulting in the stimulation of adenylyl cyclase activity. In vivo, it
was reported that both polymorphisms might contribute to
enhanced vascular reactivity to isoproterenol in capacitance vessel,
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Another SNP at nucleotide position -47, C-47T (Arg-19Cys,
rs1042711), is functionally important since it is located within a
short open reading frame, the 59-leader cistron, and affects ADRB2
expression at a translational level [8]. Studies have also identified
that C-47T polymorphism was in linkage disequilibrium (LD) with
the A46G and C79G polymorphisms in the coding region [9–11].
A substantial number of studies have previously investigated the
association between the A46G, C79G and C247T polymor-
phisms and EH risk. Several of these failed to identify any
association [11–18]. Other studies have found significant associ-
ations [9,19–24], but there is no consensus regarding which allele
was associated with hypertension or related traits. It has reported
that the GG46 genotype remarkably increased the risk for EH in
Japanese [19]. Interestingly, another study on the East Asian
population suggested that the GG46 genotype played a protective
role for EH in the Yi minority of Chinese [9]. Also, in the Han
Chinese population, consistent results have rarely been found for
particular candidate SNPs [23–25], as the Han Chinese
population was considered be intricately substructured, corre-
sponding roughly to Northern Han, Central Han, and Southern
Han, based on the populations of the geographic origins [26]. To
clarify the effect of these 3 polymorphisms on the risk of
hypertension in the Northern Han Chinese population, we
conducted a case-control study in middle-aged and older humans.
Results
Characteristics of the participants
A total of 1,137 unrelated participated subjects comprising 747
hypertensive patients (479 men and 268 women; mean age =
51.52; SD69.46) and 390 normotensive control subjects (233 men
and 157 women; mean age =51.02; SD67.66) were recruited for
the present study. The clinical and laboratory parameters of cases
and controls were summarized in Table 1. Aside from blood
pressure measurements, significant differences in body mass index
(BMI), total chelesterol, high-density lipoprotein cholesterol,
triglyceride, glucose, the ratio of drinkers were observed between
the hypertensives and the normotensives.
Association analyses
Among all the participants, 99.3% samples of C-47T polymor-
phism, 98.3% samples of A46G polymorphism and 97.7% samples
of C79G polymorphism were successfully tested in the laboratory.
No deviation from Hardy-Weinberg expectation was observed for
C-47T, A46G or C79G polymorphism in either hypertensives or
normotensives. The genotype frequencies for the 3 polymorphisms
in ADRB2 were shown in Table 2. Univariate analyses indicated
that the A46G polymorphism was significantly associated with
EH. The significantly higher prevalence of G allelic frequencies
was observed in the hypertensives than in the normotensives.
Logistic regression analysis was performed after adjusting for
confounding risk variables, that is, gender, age, BMI, total
cholesterol, high-density lipoprotein cholesterol, low-density lipo-
protein cholesterol, serum triglyceride levels, plasma glucose level,
smoking habits and drinking habits. For A46G polymorphism, we
observed a significantly higher prevalence of G allelic frequencies
(P=0.011, OR=1.287, 95%CI [1.059–1.565]) in the hyperten-
sives than the normotensives, which suggests that G allele might be
a risk factor for hypertension in the Northern Han Chinese.
Significant association could also be found in dominant genetic
model (GG+AG vs. AA, P=0.006, OR=1.497, 95%CI [1.121–
1.998]), in homozygote comparison (GG vs. AA, P=0.025,
OR=1.568, 95%CI [1.059–2.322]), and in additive genetic
model (GG vs. AG vs. AA, P=0.012, OR=1.282, 95%CI
[1.056–1.555]). No significant association could be found between
C-47T or C79G polymorphism and EH risk. (Table 3) Subgroup
analyses were performed by gender and showed that significant
effect between A46G polymorphism and EH risk could be found
in male, but not in the subgroup of female. The P-value for A46G
genotype-gender interaction was 0.617, which suggested that no
significant interaction was found. As for the C-47T or C79G
polymorphism, no significant association was found in either
subgroup. (Table 3)
Interactive effect of obesity and the ADRB2 gene
polymorphisms on hypertension
To explore the interactive effect of obesity and the ADRB2 gene
polymorphisms on hypertension, we analyzed the relation between
C-47T, A46G and C79G polymorphisms and hypertension by
stratification analyses. All the participants were divided into the
obese subgroup and the non-obese subgroup according to BMI.
The case-control study was further performed in both subgroups.
Table 4 shows the genotype distributions and allele frequencies in
obese and non-obese. As shown in Table 5, A46G polymorphism
was related to the prevalence of hypertension in the obese (GG vs.
AG vs. AA, P,0.001, OR=1.645, 95%CI [1.258–2.151]). The
association could also be found in the subgroup of obese men (GG
vs. AG vs. AA, P=0.005, OR=1.603, 95%CI [1.153–2.227]) and
obese women (GG vs. AG vs. AA, P=0.028, OR=1.739, 95%CI
[1.062–2.849]). Whereas in the non-obese subjects, no significant
association could be found between A46G polymorphism and EH
risk. The P-value for A46G genotype-BMI interaction was 0.010.
This result indicated that significant interaction existed between
A46G genotypes and obesity on hypertension. There was no
difference in genotype distribution of C-47T or C79G polymor-
Table 1. Characteristics of study participants.
Hypertension Normotension
(n=747) (n=390) P
gender, M/F 479/268 233/157 NS
age(years) 51.5269.46 51.0267.66 NS
SBP(mmHg) 153.41619.65 114.33611.07 ,0.001
DBP(mmHg) 99.18614.20 74.0468.26 ,0.001
BMI(kg/m
2) 26.8863.45 24.9063.20 ,0.001
TC(mmol/L) 5.5662.98 5.1361.07 ,0.001
HDL-C(mmol/L) 1.2660.62 1.4461.17 0.006
LDL-C(mmol/L) 3.3860.87 3.4560.78 NS
TG(mmol/L) 2.1161.36 1.6961.05 ,0.001
Glu(mmol/L) 5.3860.61 5.0860.59 ,0.001
Cr(mmol/L) 78.97618.70 77.67614.68 NS
ALT(U/L) 25.62613.19 24.48612.44 NS
HR(bpm) 71.3069.61 70.7369.20 NS
Smokers(n) 193 102 NS
Drinkers(n) 223 53 ,0.001
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass
index; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; TG, triglyceride; Glu, glucose; Cr, creatinine;
ALT, alanine aminotransferase; HR, heart rate.
Values are mean6SD.
NS indicates not significant.
doi:10.1371/journal.pone.0018590.t001
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the subgroup of the obese subjects, nor in the non-obese
participants (P.0.05).
Haplotype analyses
As shown in Figure 1, the C-47T and C79G were almost in
complete LD (D’=0.99, r
2=0.98). LD could also be found in C-
47T and A46G (D’=0.97, r
2=0.15), as well as in A46G and
C79G (D’=0.99, r
2=0.16). The Haploview program revealed C-
47T, A46G and C79G polymorphisms in the same LD block. The
haplotype analyses of the 3 polymorphisms of ADRB2 in
hypertension and control subjects were shown in Table 6. Only
three of eight possible haplotypes (T-A-C, T-G-C and C-G-G)
with frequency greater than 1% were detected in the haplotype
analyses. Global analysis revealed that significant differences in
haplotype distributions of ADRB2 gene between cases and controls
(X
2=8.49, df=2, Global P=0.014). Haplotype specific (HS)
testing showed that the T-A-C haplotype was a protective
haplotype (P=0.003, OR=0.763, 95%CI [0.639–0.912]) while
the T-G-C haplotype was observed to be a risk (P=0.015,
OR=1.265, 95%CI [1.047-1.530]). The C-G-G haplotype was
not associated with EH in the Northern Han Chinese (P=0.292).
The relative effects of the haplotypes were evaluated by the
logistic regression. As the most highly prevalent haplotype, the T-
A-C haplotype was defined as the base-line haplotype. Comparing
with the base-line haplotype, the T-G-C haplotype was associated
Table 2. The frequencies of the b2-adrenergic receptor gene C-47T, A46G and C79G polymorphisms genotypes.
Genotype (frequency,%) P* Allele (frequency,%) P**
C-47T TT CT CC T allele C allele
Case (Total) 571(77.2) 163(22.0) 6(0.8) 1305(88.2) 175(11.8)
Control (Total) 314(80.7) 68(17.5) 7(1.8) 0.358 696(89.5) 82(10.5) 0.361
Case (Male) 371(78.3) 100(21.1) 3(0.6) 842(88.8) 106(11.2)
Control (Male) 187(80.6) 41(17.7) 4(1.7) 0.723 415(89.4) 49(10.6) 0.726
Case (Female) 200(75.2) 63(23.7) 3(1.1) 463(87.0) 69(13.0)
Control (Female) 127(80.9) 27(17.2) 3(1.9) 0.289 281(89.5) 33(10.5) 0.288
A46G AA AG GG A allele G allele
Case (Total) 208(28.3) 369(50.2) 158(21.5) 785(53.4) 685(46.6)
Control (Total) 143(37.3) 174(45.4) 66(17.2) 0.003 460(60.1) 306(39.9) 0.003
Case (Male) 135(28.8) 239(51.0) 95(20.3) 509(54.3) 429(45.7)
Control (Male) 94(40.9) 98(42.6) 38(16.5) 0.006 286(62.2) 174(37.8) 0.005
Case (Female) 73(27.4) 130(48.9) 63(23.7) 276(51.9) 256(48.1)
Control (Female) 49(32.0) 76(49.7) 28(18.3) 0.167 174(56.9) 132(43.1) 0.164
C79G CC CG GG C allele G allele
Case (Total) 566(76.8) 164(22.3) 7(0.9) 1296(87.9) 178(12.1)
Control (Total) 301(80.5) 66(17.6) 7(1.9) 0.335 668(89.3) 80(10.7) 0.337
Case (Male) 367(77.9) 100(21.2) 4(0.8) 834(88.5) 108(11.5)
Control (Male) 185(80.4) 41(17.8) 4(1.7) 0.649 411(89.3) 49(10.7) 0.650
Case (Female) 199(74.8) 64(24.1) 3(1.1) 462(86.8) 70(13.2)
Control (Female) 116(80.6) 25(17.4) 3(2.1) 0.319 257(89.2) 31(10.8) 0.319
*P value of the comparison of the additive genetic model using the generalized linear model.
**P value of the comparison of allelic frequencies.
doi:10.1371/journal.pone.0018590.t002
Table 3. Odds ratios of additive genetic model comparison for each single-nucleotide polymorphism genotype associated with
essential hypertension in the Northern Han Chinese population.
Overall Male* Female*
SNP Contrast OR (95% CI) P OR (95% CI) P OR (95% CI) P
C-47T CC vs. CT vs. TT 1.012(0.746–1.374) 0.940 0.910(0.611–1.355) 0.642 1.156(0.709–1.887) 0.560
A46G GG vs. AG vs. AA 1.282(1.056–1.555) 0.012 1.332(1.037–1.709) 0.025 1.176(0.854–1.623) 0.319
C79G GG vs. CG vs. CC 1.032(0.760–1.401) 0.841 0.956(0.645–1.418) 0.825 1.138(0.692–1.873) 0.611
ORs adjusted for gender, age, body mass index, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum triglyceride levels,
plasma glucose level, smoking habits and drinking habits. OR, odds ratio; CI, confidence interval; SNP, single-nucleotide polymorphism.
*ORs adjusted for gender was not performed in Male and Female.
P-value for the interaction between A46G genotype and gender on hypertension was 0.617.
doi:10.1371/journal.pone.0018590.t003
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No association could be found between the C-G-G haplotype and
EH (P=0.089).
Discussion
The present study found that the A46G polymorphism of the
ADRB2 gene was associated with EH in the Northern Han Chinese.
G46 allele had a significantly higher representation in the cases than
in the controls. These findings were consistent with another study
among the Northern Han Chinese on stage 2 hypertension
diagnosed on systolic blood pressure (SBP)$160 mmHg and/or
diastolic blood pressure (DBP)$100 mmHg reported by Gu et al.
and Ge et al. [21,23] Compared with their study, we failed to find
significant association between C79G polymorphism and EH risk.
As the diagnostic standard of Gu et al. and Ge et al.’s study [21,23]
was higher than our current study, we considered that C79G
polymorphism might associate with more severe hypertension. Our
previous meta-analysis [27] also found the similar results, which
suggested that C79G polymorphism was associated with ‘severe
hypertension’ defined on SBP$160 mmHg and/or DBP$95
mmHg, but no significant association could be found based on
the current clinical diagnostic standard of hypertension on
SBP$140 mmHg and/or DBP$90 mmHg [2]. Interestingly,
further research was conducted to compare with Gu et al. and Ge
et al.’s study [21,23] and different results were acquired. We also
Table 4. The genotype distributions and allele frequencies of the b2-adrenergic receptor gene C-47T, A46G and C79G
polymorphisms in obese and non-obese.
Polymorphism Total (n=1137) Male (n=712) Female (n=425)
Obese (n=713)
Non-obese
(n=424) Obese (n=487)
Non-obese
(n=225) Obese (n=226)
Non-obese
(n=199)
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
(n=533) (n=180) (n=214) (n=210) (n=365) (n=122) (n=114) (n=111) (n=168) (n=58) (n=100) (n=99)
C-47T
TT (n) 397 145 174 169 277 98 94 89 120 47 80 80
CT (n) 125 32 38 36 81 23 19 18 44 9 19 18
C C ( n ) 630 43 10 33 20 1
C allele frequency 0.130 0.106 0.090 0.105 0.120 0.102 0.084 0.109 0.150 0.112 0.096 0.101
A46G
AA (n) 142 74 66 69 101 53 34 41 41 21 32 28
AG (n) 258 82 111 92 176 53 63 45 82 29 48 47
GG (n) 124 22 34 44 80 15 15 23 44 7 19 21
G allele frequency 0.483 0.354 0.424 0.439 0.471 0.343 0.415 0.417 0.509 0.377 0.434 0.464
C79G
CC (n) 395 141 171 160 275 97 92 88 120 44 79 72
CG (n) 126 32 38 34 81 23 19 18 45 9 19 16
G G ( n ) 631 43 11 33 20 1
G allele frequency 0.131 0.108 0.095 0.106 0.121 0.103 0.094 0.110 0.152 0.118 0.097 0.101
doi:10.1371/journal.pone.0018590.t004
Table 5. Stratified analyses of association between the genotypes and risk of essential hypertension in the obese and the non-
obese participants.
Total Male* Female*
SNP Population Contrast OR (95% CI) P OR (95% CI) P OR (95% CI) P
C-47T Obese CC vs. CT vs. TT 1.300(0.861–1.961) 0.211 1.138(0.672–1.923) 0.631 1.727(0.850–3.509) 0.130
Non-obese CC vs. CT vs. TT 0.708(0.430–1.166) 0.174 0.634(0.322–1.247) 0.187 0.753(0.351–1.618) 0.467
A46G Obese GG vs. AG vs. AA 1.645(1.258–2.151) ,0.001 1.603(1.153–2.227) 0.005 1.739(1.062–2.849) 0.028
Non-obese GG vs. AG vs. AA 0.927(0.688–1.248) 0.616 0.942(0.618–1.433) 0.777 0.839(0.539–1.305) 0.436
C79G Obese GG vs. CG vs. CC 1.287(0.851–1.942) 0.232 1.147(0.678–1.942) 0.609 1.647(0.810–3.356) 0.169
Non-obese GG vs. CG vs. CC 0.745(0.457–1.214) 0.236 0.722(0.380–1.374) 0.320 0.745(0.341–1.626) 0.459
ORs adjusted for gender, age, body mass index, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum triglyceride levels,
plasma glucose level, smoking habits and drinking habits. OR, odds ratio; CI, confidence interval; SNP, single-nucleotide.
*ORs adjusted for gender was not performed in sub-group analyses of Male and Female.
P-value for the interaction between A46G genotype and body mass index on hypertension was 0.010.
doi:10.1371/journal.pone.0018590.t005
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and 441 patients were included. The patients’ genotypes were
compared with that of the normotensive subjects and logistic
regression analysis was also performed after adjusting for con-
founding risk variables. There was no difference in genotype
distribution of C79G between the cases and the controls (GG vs.
CG vs. CC, P=0.454, OR=0.873, 95%CI [0.613–1.244]). We
thought that this discrepancy might be resulted from 2 main
reasons. Firstly, the participants of the stage 2 hypertension
subgroup in the current study were fewer than that of Gu et al.
and Ge et al.’s. For the low frequency of the uncommon allele of
C79G, extremely large trial size was required for enough statistical
power to detect real differences between groups[28]. The P-values
of the case-control studies might have been a statistical fluctuation
by chance owing to the nature of random sampling, dependent on
the sample size and the low minor allele frequency of C79G.
Secondly, different results might be partially attributed to the
complex genetic differentiation among the Northern Han Chinese
population[29]. We found almost complete LD between C79G and
C-47T polymorphisms,whereasweak LDwasfound inGu etal.and
Ge et al.’s study. As for the C-47T polymorphism, both studies got
negative results. Negative results were also found on C79G
polymorphism in our case-control study since it was almost in
complete LDwithC-47T,whichwasdifferentfromGu etal.andGe
et al.’s. Previous research also reported different degree of LD
between C79G and C-47T in different ethnic background
subjects[22,30–32]. With the human migration in the history, the
Northern Han Chinese population was under strong genetic
influences from other populations[29]. The samples from our study
and Gu et al. and Ge et al.’s were not entirely enrolled from the same
area, the participants were not in a single homogenous popula-
tion[26,29], which might result in different association in these
studies.
Stratification analyses showed that A46G polymorphism was
association with EH risk in male, but not in the female population.
No significant interaction existed between A46G genotype and
gender. Yet we suggested that the different results between men and
women and the P-value for genotype-gender interaction should be
treated cautiously, as the women participants in this study were
considerably smaller than men, which might limit the power to
detect differences in OR estimates between the subgroups.
Stratification analyses on obesity found the association between
A46G polymorphism and EH risk in the obese subgroup, both in
obese men and in obese women, whereas in the non-obese
population, no association could be found. Significant interaction
Figure 1. Linkage disequilibrium (LD) block defined by the
Haploview program based on the confidence interval method.
a represents LD measure of D’. b represents LD measure of r
2.
doi:10.1371/journal.pone.0018590.g001
Table 6. Haplotype analyses of the b2-adrenergic receptor gene polymorphisms in hypertension and control subjects.
Haplotype frequency
C-47T A46G C79G Cases Controls HS test P value
a OR [95% CI]
a P value
b
OR [95%
CI]
b
Global P
value
c
T A C 0.534 0.600 0.003 0.763 [0.639–0.912] - - 0.014
T G C 0.345 0.294 0.015 1.265 [1.047–1.530] 0.005 1.319 [1.085–
1.604]
C G G 0.121 0.106 0.292 1.162 [0.879–1.537] 0.089 1.284 [0.963–
1.713]
All haplotypes with frequency greater than 1% detected in the haplotype analyses are shown in the table.
HS test, haplotype specific testing; OR, odds ratio; CI, confidence interval.
aP values and OR values derived from comparing of a specific haplotype with the other two.
bP values and OR values derived from comparing each haplotype with the base-line haplotype (T-A-C).
cP value for global test comparing model with haplotypes to model without.
doi:10.1371/journal.pone.0018590.t006
ADRB2 Polymorphisms and Hypertension
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18590could also be found between A46G genotypes and BMI on EH risk.
These findings suggested that obesity might have an effect on the
association between genetic factors and EH risk. Mo et al. [25]
compared the obese hypertensive population and the non-obese
normotensivecontrols intheSouthernHanChinesepopulationand
indicated that the association could be found on C79G polymor-
phism in male, whereas no association was found on A46G
polymorphism. We considered that the deviation between these 2
studies was mainly on the obesity effect. We performed stratification
analyses and compared on the obese hypertension and the obese
normotension, which was different from Mo et al.’s comparison on
the control subjects. When both research studied on the same kind
of participants, the non-obese population, and compared between
hypertension and normotension, our findings were consistent with
Mo et al.’s result. Furthermore, with the genetic background
difference [26,33–35] and the different environmental factors, such
as eating habits, lifestyle, geographical localities and climate
between the Northern and the Southern Han Chinese population,
the results of these 2 studies might also be different.
Compared with the studies on Caucasians [11,12,15–17], most
of them indicated ‘negative’ results on A46G polymorphism and
EH risk. It was reported that the allele frequencies of the C-47T,
A46G and C79G polymorphisms were quite different among
ethnicities [36]. In the Asian populations, the allele frequencies of
C-47, G46 and G79 were significantly lower than that of the
Caucasians and the Blacks. The heterogeneity of allelic frequencies
among the ethnicities might be the main point of the different
results in the case-control studies. Beside this, the environment risk
factors should also be taken into consideration. In the present
study, A46G polymorphism was associated with EH risk in the
obese population. This might be related to the living habits and
environments of the obese. So we considered that the association
might be the result of gene-environment interaction.
Haplotype analyses suggested that only 3 haplotypes with
frequency greater than 1% were found in the study as previously
described [30,37]. As the haplotype frequencies listed in Table 6,
the haplotype frequencies summed to 100%, both in cases and in
controls, which meant that there was almost no rare haplotypes
detected in the current study. This was attributed to the close LD
of the C-47T, A46G and C79G polymorphisms. It was reported
that subjects homozygous for G79 were nearly always homozygous
G46, whereas A46/G79 occurred naturally extremely rare [38–
40]. In our study, no AA46/GG79 combined genotype was found.
As for the LD of C-47T and C79G, Lima et al. [30] reported that
these two polymorphisms were in complete LD in whites and
African Americans. In the current research, similar result was
observed in Northern Han Chinese. In the 1105 subjects (97.2% of
all the participants), whose genotypes of both the C-47T and
C79G polymorphisms were successfully detected, only 4 subjects
were deviated from the consistent genotype of mutant with mutant
or wild-type with wild-type on these 2 tight LD polymorphisms.
For the reasons of the high consistency of the C-47T and C79G
polymorphisms, and of the low frequencies of both uncommon
alleles, in the case-control study, the results of the haplotype
analyses on the C-47T, A46G and C79G polymorphisms might be
particularly determined by the allelic variants of the A46G
polymorphism. Haplotype analyses showed that the T-A-C
haplotype was a protective haplotype and the T-G-C haplotype
was a risk, which was consistent with the findings of the association
analyses between the A46G polymorphism and EH risk. For only
3 haplotypes detected, we could hardly perform further compar-
isons on multiple hypotype combinations.
As Green et al. reported [7], either the G46 allele or the G79
allele, compared to their wild allele, displayed normal agonist
binding and functional coupling to Gs, resulting in the stimulation
of adenylyl cyclase activity. In the downregulation of ADRB2, the
A46G and the C79G polymorphisms played roles in the different
degree. As compared to the wild-type AA46, the GG46 underwent
a greater degree of downregulation of ADRB2 in response to the
b2-agonist isoproterenol. These findings suggested that for the
reason of decrease agonist sensitivity, an increased blood pressure
might be produced by the GG46. On the contrary, the GG79,
compared to the wild-type CC79, displayed no downregulation of
ADRB2. Interestingly, the receptor with the GG46/GG79
combined genotype also displayed a greater degree of downreg-
ulation as compared to that found with the AA46/CC79
combined wild-type. Our results were in agreement with these
findings. However, Wu et al. [9] studied on two Southern Chinese
minority human population and got the different conclusions.
They found that both the A46G and the C79G polymorphisms
could play a role in the blood pressure regulation in the Yi, not in
the Hani, minority group. In the Yi minority, the G46 allele and
the G79 allele were more frequent in the control groups than in
the hypertensive participants. Compared to Han Chinese, Yi and
Hani minority groups have different ethnic origins [41], and living
in a particular geographical environment. So we considered that
the different results were probably due to the differences in
ethnicity and geographical conditions.
It was reported [42] that the C-47T variant in the promoter
region of the ADRB2 gene controlled the ADRB2 expression. The
T-47 allele resulted in increased expression of the ADRB2 as
compared with the C-47 allele. As the LD between the C-47T
polymorphism and the ADRB2 gene coding block polymorphisms
A46G and C79G, it suggested that the allele frequency of the C-
47T polymorphism associated with that of the A46G and C79G
polymorphisms. In other words, the A46G and the C79G variants
within the coding region were thought to affect the ADRB2 gene
expression. The current study found that the A46G polymor-
phism, but not the C79G or C-47T polymorphism, associated with
the risk of EH in the Northern Han Chinese population. However,
for the tight LD between multiple polymorphisms on the ADRB2
gene, we believe that the A46G polymorphism should not be
independently considered as the impact factor of the ADRB2 gene
on the pathogenesis of EH. Further research on the role of the
multiple polymorphisms of different regions within the ADRB2
gene in the pathophysiologic of EH are important to clarify the
genetic mechanism of EH.
Compared with early studies, the sample size of the present
study was moderate. However, for the minor allele frequencies of
C-47T, A46G and C79G of the Asians were significantly lower
than that of the Caucasians and the Blacks as previously reported
[36], and the allele frequencies of C-47 and G79 were much lower
than G46, the statistical power to detect a significant association
on C-47T and C79G polymorphisms were limited. The current
study found that the 3 polymorphisms were in tight LD, but in the
association study of EH, the results were quite different, both in all
the participants and in the subgroups analyses. With the limited
statistical power, the conclusions on C-47T and C79G polymor-
phisms should be treated cautiously. Considering the vastly
different allele frequencies of the ADRB2 gene polymorphisms in
different ethnicities and the low minor allele frequencies of C-47T
and C79G polymorphisms, larger case-control studies stratified for
different ethnicities should be performed to clarify the association
between the ADRB2 gene polymorphisms and EH risk in the
future.
In conclusion, we found that the A46G polymorphism in the
ADRB2 gene significantly associated with EH risk among the
Northern Han Chinese population. The G46 allele was a risk
ADRB2 Polymorphisms and Hypertension
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that this association could be found in male, but not in female.
Stratification analyses by obesity showed that G46 allele was
related to the prevalence of hypertension in the obese population.
Significant interaction existed between A46G genotypes and BMI
on EH. Haplotype analyses suggested that the T-47-A46-C79
haplotype was a protective haplotype for EH, while the T-47-G46-
C79 haplotype increased the risk of EH. Furthermore, for the tight
LD between the polymorphisms in the ADRB2 gene, further
research is warranted to elucidate the role of the multiple
polymorphisms within the ADRB2 gene in the mechanism of EH.
Materials and Methods
Ethics Statement
The study complies with the Declaration of Helsinki, the local
ethics committee of Beijing Anzhen Hospital of the Capital
University of Medical Sciences has approved the research
protocol. Written informed consent was obtained from each
participant.
Subjects
All individuals were of Northern Han Chinese origin and from
the Beijing area recruited range from June 2008 to June 2009 in
this study. All the participants were ascertained and identified via
Anzhen Hospital of the Capital University of Medical Sciences,
Beijing, China (n=859), and two examination centers at local
health stations, Liuliqiao (n=71) and Guozhuang (n=207), in
Beijing suburbs.
Blood pressure was measured by trained and certified observers
according to a common protocol adapted from procedures
recommended by European Society of Hypertension [2]. After
sitting for 30 min in a quiet room, three measurements with a
standardized mercury sphygmomanometer were performed at
least 5 min intervals. One of the 4 bladders (standard, larger,
smaller, pediatric) was chosen and all readings were obtained from
the right arm. SBP and DBP were defined according to Korotkoff
I and V. Heart rate was measured by pulse palpation 30 sec
after the measurement of blood pressure. Hypertension was
defined as the average SBP.140 mmHg and/or the average
DBP.90 mmHg and/or self-reported current treatment for
hypertension with antihypertensive medication. The control
subjects had systolic and diastolic blood pressures ,140 mmHg
and ,90 mmHg, respectively, and should never been treated for
hypertension [2]. Subjects with secondary hypertension, primary
renal disease, diabetes mellitus, hepatic disorders, cancer,
endocrine diseases such as hyperthyroidism were excluded.
Physical examination, a questionnaire and serum biochemical
profile were administered to each of the participants. Information
on smoking and drinking habits was obtained by interview.
Smoker was defined as the cigarette consumer who has smoked
$100 cigarettes, and drinker was defined as the alcohol consumer
who drank $12 times during the year [21,23]. Obese was defined
as a BMI $25 kg/m
2 according to the World Health Organiza-
tion obesity guidelines on Asians [25,43,44].
Genotyping
Blood was taken into EDTA-containing receptacles. Genomic
DNA was extracted from peripheral blood according to standard
phenol-chloroform methods. We genotyped SNPs using the
TaqMan assay. The ADRB2 SNP Taqman probes and primers
were obtained from Applied Biosystems Assay-by-Design Service
for SNP genotyping. The sample DNA was amplified by PCR
following the recommendations of the manufacturer. Thermal
cycling was done on a GeneAmp PCR System 9700 thermal cycler
(Applied Biosystems, 850 Lincoln Centre Drive, Foster City, CA
94404 USA). Genotypes were differentiated by analyzing the
fluorescence levels of PCR products using an ABI PRISM
7900HT Sequence Detector (Applied Biosystems). Genotyping
was performed blindly to all other data.
Statistical Analyses for Patient–Control Study
We used SPSS (Version 17.0; SPSS, Chicago, Illinois) for
database management and statistical analyses. All comparisons
between specific groups for continuous variables were made using
a two-sample t-test. Allelic and genotypic frequencies were
compared between the hypertensive cases and the normotensive
controls by using the chi-square test. Genotype frequency of the
subjects specified by different genetic models (additive, dominant,
recessive and homozygote comparison) was analyzed by multivar-
iate logistic regression adjusted for covariates. Analyses used two-
tailed estimation of significance. The statistical significance was
defined P,0.05.
The presence of Hardy–Weinberg equilibrium was tested by the
chi-square test for goodness of fit based on a web program (http://
ihg.gsf.de/cgi-bin/hw/hwa1.pl).
Construction of the LDmap and haplotype blocks within C-
47T, A46G and C79G polymorphisms of the ADRB2 gene was
based on genotypes and utilized Haploview software (version 4.1)
(http://www.broad.mit.edu/mpg/haploview/) [45]. The expecta-
tion maximization algorithm [46] was performed to estimate
haplotype frequencies and to obtain the best haplotype configu-
ration for each multi-locus genotype. All haplotypes with
frequency greater than 1% in the combined case and control
samples were examined. The chi-square test was conducted to
compare the haplotype distributions between the hypertensives
and the normotensives. HS testing was performed to compare a
specific haplotype with the others. Assuming the highly prevalent
haplotype as the base line, each of the other haplotype was also
compared with the base-line haplotype using a logistic regression
model. A global test statistic comparing the model with genetic
data to the model without genetic data was also performed to
check for the overall association of haplotypes with the disease
outcome, using an online computer platform SHEsis (http://
analysis.bio-x.cn/myAnalysis.php) [47,48].
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